Investing in a Cure
Steven St. Peter discusses how venture philanthropy, impact investing and venture capital can work together to support IBD innovation.
Vie VenturesNov 16, 2026
Vie Ventures at FASI-10 Summit: Challenges and Opportunities in Food Allergy Drug Development
Vie VenturesOct 24, 2026
Luke Evnin at Cool Comedy • Hot Cuisine
Vie VenturesOct 13, 2026
Jeff Bluestone Honored with the 2026 UCSF Medal
Jeff Bluestone receives UCSF’s highest honor in recognition of his contributions to immunology and the translation of scientific discoveries into new therapies.
Vie VenturesSep 11, 2026
Boom Times For Autoimmune Disease Therapies
ForbesJul 8, 2026
Food Allergy Science Initiative and Vie Ventures Announce Strategic Collaboration to Accelerate Progress Toward a Cure for Food Allergies
Business WireJun 23, 2026
Vie Ventures Looks To Fill Autoimmune Disease Funding Gap
In VivoMay 19, 2026
20 Voices: What Does 2026 Hold For Biopharma?
In VivoFeb 23, 2026
Treg pioneer Bluestone joins Vie Ventures as it builds autoimmune portfolio
BioCenturyFeb 19, 2026
Vie Ventures Names Jeff Bluestone, PhD, as Managing Director
Vie VenturesFeb 19, 2026
Interview with Vie Ventures Co-Founders Dr. Steven St. Peter and Dr. Luke Evnin and Senior Advisor Dr. Louis DeGennaro
Close EncountersJan 21, 2026
Catalytic Capital in Biotech & VC Philanthropy: Redefining purpose-aligned capital
YouTubeDec 17, 2025
Two veterans from MPM launch Vie Ventures to invest in the I&I space, leveraging disease-specific philanthropies
BioTech TVDec 5, 2025
A Venture Fund that Leverages Patient Experts to Target Autoimmune Diseases
Global Genes · RARECastNov 26, 2025
Vie Ventures Convenes Inaugural Therapeutics Advisory Council to Advance Collaboration Among Autoimmune Disease Ecosystems
Vie VenturesSep 17, 2025
Therapeutics Advisory Council Seeks to Drive Innovation in Autoimmune Disease Treatment
Vie Ventures BlogSep 16, 2025
Vie Ventures Launches to Bankroll Autoimmune-Disease Biotechs
The Wall Street JournalJul 9, 2025
Veteran venture capitalists launch new firm to Vie for autoimmune success
FierceBiotechJul 9, 2025
Vie Ventures, New Life Sciences Venture Capital Firm, Launches to Advance Next Generation Therapies for Autoimmune Diseases
Vie VenturesJul 9, 2025
Building the future of autoimmune therapeutics.
Whether you are a prospective investor, a strategic collaborator, or a company creating next-generation therapies, we would be glad to connect.
Or email us directly at contact@vieventures.com.

